BR112018074119A2 - método de tratamento de câncer através de alvejamento de células supressoras derivadas de mieloide - Google Patents

método de tratamento de câncer através de alvejamento de células supressoras derivadas de mieloide

Info

Publication number
BR112018074119A2
BR112018074119A2 BR112018074119-1A BR112018074119A BR112018074119A2 BR 112018074119 A2 BR112018074119 A2 BR 112018074119A2 BR 112018074119 A BR112018074119 A BR 112018074119A BR 112018074119 A2 BR112018074119 A2 BR 112018074119A2
Authority
BR
Brazil
Prior art keywords
suppressor cells
derived suppressor
treatment method
cancer treatment
targeting myeloid
Prior art date
Application number
BR112018074119-1A
Other languages
English (en)
Inventor
Stewart Low Philip
Wang Bingbing
Paul Leamon Christopher
J. Lu Yingjuan
W. Wheeler Ii Leroy
Original Assignee
Purdue Research Foundation
Endocyte, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation, Endocyte, Inc. filed Critical Purdue Research Foundation
Publication of BR112018074119A2 publication Critical patent/BR112018074119A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

a presente invenção refere-se a métodos para tratamento de um câncer usando um ou mais compostos compreendendo um ligante de ligação de receptor folato ligado a um fármaco via um ligante. mais particularmente, a invenção aqui descrita se refere a métodos para tratamento de um câncer usando um ou mais compostos compreendendo um ligante de ligação de receptor folato ligado a um fármaco via um ligante para alvejar células supressoras derivadas - mieloide.
BR112018074119-1A 2016-05-25 2017-05-25 método de tratamento de câncer através de alvejamento de células supressoras derivadas de mieloide BR112018074119A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341587P 2016-05-25 2016-05-25
US62/341,587 2016-05-25
PCT/US2017/034537 WO2017205661A1 (en) 2016-05-25 2017-05-25 Method of treating cancer by targeting myeloid-derived suppressor cells

Publications (1)

Publication Number Publication Date
BR112018074119A2 true BR112018074119A2 (pt) 2019-03-06

Family

ID=60412652

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018074119-1A BR112018074119A2 (pt) 2016-05-25 2017-05-25 método de tratamento de câncer através de alvejamento de células supressoras derivadas de mieloide

Country Status (10)

Country Link
US (2) US20190216935A1 (pt)
EP (1) EP3463367A4 (pt)
JP (1) JP7278777B2 (pt)
KR (1) KR102489277B1 (pt)
CN (2) CN109475558A (pt)
AU (1) AU2017271550B2 (pt)
BR (1) BR112018074119A2 (pt)
CA (1) CA3025309A1 (pt)
IL (1) IL263059A (pt)
WO (1) WO2017205661A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210308267A1 (en) * 2018-08-07 2021-10-07 Purdue Research Foundation Rejuvenation of car t cell
US20220331434A1 (en) * 2019-07-08 2022-10-20 Purdue Research Foundation Compounds and methods for the treatment and prevention of fibrotic disease states and cancer
CN116283709A (zh) * 2023-01-13 2023-06-23 华中科技大学同济医学院附属同济医院 一种脂滴包被蛋白3的抑制剂及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2468240T3 (es) * 2005-08-19 2014-06-16 Endocyte, Inc. Conjugados de ligando de múltiples fármacos
US20120128587A1 (en) * 2009-07-31 2012-05-24 Endocyte, Inc. Folate-targeted diagnostics and treatment
EP2547366A4 (en) * 2010-03-18 2013-08-07 Univ Colorado State Res Found INHIBITING AGENTS OF SUPPRESSIVE MYELOID CELLS
CN109517897A (zh) * 2011-04-28 2019-03-26 南加利福尼亚大学 人类髓源抑制性细胞癌症标记
US9550992B2 (en) * 2011-12-02 2017-01-24 University Of South Florida Compositions and methods for modulating myeloid derived suppressor cells
WO2013169913A1 (en) * 2012-05-08 2013-11-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Predictors of patient response to interferon-a therapy
AU2013331440A1 (en) * 2012-10-16 2015-04-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
WO2016027273A1 (en) * 2014-08-19 2016-02-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Methods for predicting and monitoring cancer patients' response to treatment by measuring myeloid derived suppressor cells (mdscs)
WO2016085967A1 (en) * 2014-11-25 2016-06-02 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages
CN107847609A (zh) * 2015-03-13 2018-03-27 恩多塞特公司 用于治疗疾病的缀合物

Also Published As

Publication number Publication date
RU2018145750A3 (pt) 2020-07-30
JP7278777B2 (ja) 2023-05-22
KR102489277B1 (ko) 2023-01-16
RU2018145750A (ru) 2020-06-25
IL263059A (en) 2018-12-31
CN114903890A (zh) 2022-08-16
JP2019519524A (ja) 2019-07-11
KR20190021261A (ko) 2019-03-05
CN109475558A (zh) 2019-03-15
US20210170035A1 (en) 2021-06-10
AU2017271550B2 (en) 2023-11-02
EP3463367A4 (en) 2020-01-29
US20190216935A1 (en) 2019-07-18
CA3025309A1 (en) 2017-11-30
EP3463367A1 (en) 2019-04-10
AU2017271550A1 (en) 2018-12-06
WO2017205661A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
IL263497B (en) 1-tetrahydropyranylcarbonyl-3,2-dihydro-h1-indole compounds for cancer treatment
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
SI3456717T1 (sl) 4,6-diamino-kinolin-3-karbonitrilni derivat kot modulator cancer osaka thyroid (COT) za zdravljenje vnetne bolezni
PH12016502607A1 (en) Functionalised and substituted indoles as anti-cancer agents
MX2020006668A (es) Anticuerpos para lilrb2.
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
BR112018015836A2 (pt) administração de células t engenheiradas para tratamento de cânceres no sistema nervoso central
EA201792443A1 (ru) МОДУЛЯТОРЫ K-Ras
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
EA201790173A1 (ru) Антитела, связывающие axl
IL260935A (en) Methods for treating hrg, her2-, er breast cancer using combined treatments that include an anti-erbb3 antibody
EA201692568A1 (ru) Составы с полипептидами-рецепторами и связанные с ними способы
PH12016500967A1 (en) Functionalised and substituted indoles as anti-cancer agents
PH12017502237A1 (en) Nuclear receptor modulators
EA201991818A1 (ru) Лечение рака
EA201791203A1 (ru) ЛЕКАРСТВЕННЫЙ КОНЪЮГАТ АНТИТЕЛА ПРОТИВ с-МЕТ
CO2019000753A2 (es) Métodos para tratar el cáncer de próstata
AU2016362202A8 (en) Method for preventing or treating nosocomial pneumonia
BR112018074119A2 (pt) método de tratamento de câncer através de alvejamento de células supressoras derivadas de mieloide
BR112016029460A2 (pt) métodos para tratar artrite reumatoide
CL2019001526A1 (es) Métodos para el tratamiento de la enfermedad renal poliquística.
IL288135A (en) Compounds containing bisfluoroalkyl-1,4-benzodiazepines for the treatment of breast cancer characterized by Notch activation
CA2947310C (en) Microparticles for treating renal cell carcinoma
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]